Haemophilus influenzae type b capsular polysaccharide conjugated to carrier protein (Hib-PRP conjugate)

The Haemophilus influenzae type b capsular polysaccharide conjugated to carrier protein is the antigenic component used in Hib conjugate vaccines, designed to prevent invasive disease caused by Haemophilus influenzae type b, a major childhood pathogen that can cause meningitis, pneumonia, epiglottitis, and sepsis[2][6][8][9]. The principal antigen is polyribosyl ribitol phosphate (PRP), a high-molecular-weight polysaccharide from the bacterial capsule, which by itself is poorly immunogenic in infants. To elicit a protective antibody response in young children, PRP is chemically linked (conjugated) to a protein carrier, most commonly tetanus toxoid, diphtheria toxoid (CRM197 mutant), or outer membrane protein from Neisseria meningitidis[4][6][7][8][9]. This conjugation converts the polysaccharide into a thymus-dependent antigen capable of stimulating strong, lasting immune responses and immunological memory[1][2][6]. This entry is not a molecular therapeutic target but an immunogen used in licensed vaccines, and not a native protein, receptor, enzyme, or classic drug target. The entity described is a vaccine antigen, not a therapeutic target such as a receptor, enzyme, or transporter[1][2][6][9]. This makes is_target: false and is_incorrect: true (based on your definition, as it is a vaccine component, not a pharmacological target). Common molecular target categories (receptor, ion channel, etc.) do not apply; it is best classified under “Other” for molecular_classifications. The “mechanism of action” for drugs targeting this molecule is not applicable, but the mechanism of immune protection is via antibody induction. “Interacting drugs” are not relevant, as there are no drugs targeting this molecule directly; it is part of a vaccine, not a drug target. This entry refers to the Hib conjugate vaccine antigen, not to a typical therapeutic molecular target or receptor, and should not be considered a conventional drug target for pharmacological intervention[2][6][9].

Other names

Hib-PRP conjugate vaccineHib conjugatePRP-conjugateHaemophilus b conjugate vaccineHib polysaccharide-protein conjugate

Induction of anti-PRP antibody production via T cell–dependent immune response after conjugation to a carrier protein[2][6][9]